TargetBeta
PDCD1
programmed cell death 1 · also CD279, PD1, hSLE1, PD-1 · CD molecules
54 programs in company-led studies act on PDCD1, from 41 companies: 28 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (41 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 31 programs
- Colorectal Neoplasms, 12 programs
- Stomach Neoplasms, 12 programs
- Carcinoma, Hepatocellular, 11 programs
- Uterine Cervical Neoplasms, 10 programs
- Melanoma, 9 programs
- Neoplasms, 6 programs
- Small Cell Lung Carcinoma, 6 programs
- Squamous Cell Carcinoma of Head and Neck, 6 programs
- Ovarian Neoplasms, 5 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026cadonilimab · Akeso · phase 3 · NCT06341335
- Nov 2026tislelizumab · BeOne Medicines · phase 3 · NCT03736889
- Nov 2026Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 · Sino Biopharmaceutical · phase 3 · NCT06767813
- Nov 2026TQB2252 · Sino Biopharmaceutical · phase 1 · NCT06649656
- Nov 20, 2026pembrolizumab · Merck · phase 4 · NCT04634877
- Nov 23, 2026dostarlimab · GlaxoSmithKline · phase 4 · NCT06567782
- Nov 30, 2026Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 · Innovent Biologics · phase 3 · NCT07122687
- Nov 30, 2026Anti-PD-1/IL-15 Fusion Protein JMT108 · CSPC Pharmaceutical Group · phase 2 · NCT07280832
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.